Similar articles for PMID: 31003697

Year	Number of Results
2012	3
2013	5
2014	2
2015	10
2016	15
2017	22
2018	23
2019	15
2020	12
2021	13
2022	2
2023	1
2024	0

1

Rapid Onset of Tofacitinib Induction Therapy for the Treatment of Ulcerative Colitis.

Griller N, Cohen L. Griller N, et al. Clin Gastroenterol Hepatol. 2019 May;17(6):1213. doi: 10.1016/j.cgh.2018.11.038. Clin Gastroenterol Hepatol. 2019. PMID: 31003697 No abstract available.

2

Efficacy of tofacitinib treatment in ulcerative colitis.

Panés J, Gisbert JP. Panés J, et al. Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14. Gastroenterol Hepatol. 2019. PMID: 31101342 Free article. Review. English, Spanish.

3

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.

Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Hanauer S, et al. Clin Gastroenterol Hepatol. 2019 Jan;17(1):139-147. doi: 10.1016/j.cgh.2018.07.009. Epub 2018 Sep 10. Clin Gastroenterol Hepatol. 2019. PMID: 30012431 Free article.

4

Tofacitinib for the treatment of ulcerative colitis.

Fernández-Clotet A, Castro-Poceiro J, Panés J. Fernández-Clotet A, et al. Expert Rev Clin Immunol. 2018 Nov;14(11):881-892. doi: 10.1080/1744666X.2018.1532291. Epub 2018 Oct 11. Expert Rev Clin Immunol. 2018. PMID: 30285500 Review.

5

Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy.

Esfahani K, Hudson M, Batist G. Esfahani K, et al. N Engl J Med. 2020 Jun 11;382(24):2374-2375. doi: 10.1056/NEJMc2002527. N Engl J Med. 2020. PMID: 32521140 No abstract available.

6

IBD: Tofacitinib effective in ulcerative colitis.

Bradley CA. Bradley CA. Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):388. doi: 10.1038/nrgastro.2017.66. Epub 2017 May 17. Nat Rev Gastroenterol Hepatol. 2017. PMID: 28513630 No abstract available.

7

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?

Tsai HH. Tsai HH. Aliment Pharmacol Ther. 2018 Feb;47(4):539-540. doi: 10.1111/apt.14480. Aliment Pharmacol Ther. 2018. PMID: 29341281 No abstract available.

8

Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.

Le Berre C, Loeuille D, Peyrin-Biroulet L. Le Berre C, et al. Clin Gastroenterol Hepatol. 2019 Mar;17(4):794-796. doi: 10.1016/j.cgh.2018.08.017. Epub 2018 Aug 13. Clin Gastroenterol Hepatol. 2019. PMID: 30114486 No abstract available.

9

Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.

Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Bonovas S, et al. Aliment Pharmacol Ther. 2018 Feb;47(4):540-541. doi: 10.1111/apt.14486. Aliment Pharmacol Ther. 2018. PMID: 29341277 No abstract available.

10

Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice.

Kotze PG, Teixeira FV, Damião AOMC. Kotze PG, et al. Aliment Pharmacol Ther. 2020 Jun;51(11):1208-1209. doi: 10.1111/apt.15652. Aliment Pharmacol Ther. 2020. PMID: 32424919 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year